论文部分内容阅读
目的:总结近年来国内外对中晚期肝细胞肝癌靶向治疗的研究进展。方法:应用计算机检索CHKD期刊全文数据库及PubMed检索系统,以“肝细胞肝癌”和“治疗进展”为关键词检索2007-01-2009-11相关肝细胞肝癌中晚期治疗进展的文献。纳入标准:1)肝细胞肝癌的病因、分布及分子生物学形成机制;2)原发性肝癌的分期研究及对治疗的指导;3)肝细胞肝癌的靶向、化疗及免疫治疗理念进展。根据纳入标准纳入分析24篇文献。结果:针对肝细胞肝癌肿瘤血管形成机制及多信号转导途径的分子靶向治疗被证实为可以有效延长患者生存期,成为中晚期肝细胞肝癌治疗新方向。结论:靶向药物相互联合或联合化疗成为治疗趋势;探讨对索拉非尼等药物的相对特异的生物学标志可更好地筛选敏感治疗人群。
OBJECTIVE: To summarize recent advances in targeted therapy of hepatocellular carcinoma in both advanced stage and advanced stage in China. METHODS: The full-text database of CHKD periodicals and PubMed retrieval system were searched by computer, and the key words of “Hepatocellular carcinoma” and “Progress of treatment” were retrieved from January 2007 to January 2009 in the literature. . Inclusion criteria: 1) the etiology, distribution and molecular biology of hepatocellular carcinoma; 2) the staging of primary liver cancer and the guidance of treatment; 3) the progress of the concept of targeting, chemotherapy and immunotherapy of hepatocellular carcinoma. According to inclusion criteria analysis of 24 articles. Results: Targeted molecular targeted therapy of hepatocarcinoma tumor angiogenesis and multiple signal transduction pathways proved to be effective in prolonging survival and becoming a new direction for the treatment of advanced hepatocellular carcinoma. CONCLUSIONS: Targeted drug combination or combination chemotherapy is the trend of treatment. To explore the specific biological markers of sorafenib and other drugs can better screen the sensitive treatment population.